These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 21063824)
1. [10 years of treatment with TNF inhibitors--are we on the safe side?]. Zink A; Schneider M Z Rheumatol; 2010 Nov; 69(9):772-3. PubMed ID: 21063824 [No Abstract] [Full Text] [Related]
2. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380 [No Abstract] [Full Text] [Related]
3. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease]. Mariette X Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603 [No Abstract] [Full Text] [Related]
4. [Evidence based medicine in rheumatology]. Gause A; Raspe HH Z Rheumatol; 2002 Oct; 61(5):516-8. PubMed ID: 12399877 [No Abstract] [Full Text] [Related]
12. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade. Yelin E; Katz P Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010 [No Abstract] [Full Text] [Related]
13. Three years experience with the prescription of anti-TNF-alpha inhibitors at Dr Soliman Fakeeh Hospital in Jeddah, Saudi Arabia. Eleishi HH; Toma NF; Chaki MC; Nada HR Int J Rheum Dis; 2009 Apr; 12(1):14-9. PubMed ID: 20374311 [TBL] [Abstract][Full Text] [Related]
14. Update in rheumatology: evidence published in 2011. Forbess LJ; Bass AR Ann Intern Med; 2012 Jul; 157(2):114-9. PubMed ID: 22801673 [No Abstract] [Full Text] [Related]
15. Effectiveness of biologics in rheumatology: improving the evidence base. Silman AJ; Ades AE Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv1-2. PubMed ID: 21859699 [No Abstract] [Full Text] [Related]
16. Is there a rationale for switching from one anti-tumor necrosis factor agent to another? Haraoui B J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907 [No Abstract] [Full Text] [Related]
17. Rheumatoid vasculitis treated with infliximab. van der Bijl AE; Allaart CF; Van Vugt J; Van Duinen S; Breedveld FC J Rheumatol; 2005 Aug; 32(8):1607-9. PubMed ID: 16078342 [TBL] [Abstract][Full Text] [Related]
18. Should tuberculin skin test be positive to give latent tuberculosis treatment before tumor necrosis factor-alpha inhibitors in selected patients in developing countries? Abud-Mendoza C; Martínez-Martínez MU; DE Jesús Macías-Mendoza J; Magaña-Aquino M J Rheumatol; 2010 Mar; 37(3):672-3; author reply 673. PubMed ID: 20197567 [No Abstract] [Full Text] [Related]